Navigation Links
Yaupon Therapeutics Completes Patient Enrollment for Pivotal Phase 2 Study of Clearazide for Treatment of Cutaneous T-cell Lymphoma
Date:6/29/2009

Largest clinical study ever involving patients with cutaneous T-cell lymphoma on schedule for completion in June 2010

RADNOR, Pa., June 29 /PRNewswire/ -- Yaupon Therapeutics, a privately held specialty pharmaceutical company, has announced it has completed enrollment for a pivotal Phase 2 clinical trial for Clearazide for the treatment of early-stage cutaneous T-cell lymphoma (CTCL - stages 1-2a). The study, which is being conducted under a Special Protocol Assessment (SPA) with the FDA, has enrolled 260 patients in 13 of the top cancer centers in the US. Yaupon expects the last patient to complete treatment in the study by June of 2010 and, assuming positive results, will file its NDA shortly thereafter.

The randomized, double-blind, controlled clinical study is the largest ever undertaken involving patients with cutaneous T-cell lymphoma. Over one percent (1%) of all people with CTCL in the United States have enrolled in the study. There are approximately 16,000 to 20,000 patients with CTCL in the United States and each year approximately 2,000 people are newly diagnosed with the disease. If approved by FDA, Clearazide would be the first new therapy available for the treatment of early-stage CTCL in almost a decade.

"Cutaneous T-cell lymphoma, like all cancers, is a terrible burden on families worldwide. Completion of patient enrollment in this landmark study is a major milestone in our efforts to advance Clearazide through regulatory approval and to help patients with CTCL. We look forward to completing this study and filing our NDA next year," said Robert J. Alonso, Chief Executive Officer of Yaupon.

Cutaneous T-cell lymphoma is a cancer of the T-lymphocytes in the skin. Early-stage CTCL (stages 1-2a) is the most common presentation of the cancer and affects roughly 67% of the 20,000 patients with the disease. CTCL is a low-grade lymphoma and usually develops very slowly. It
'/>"/>

SOURCE Yaupon Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014 Research and ... "Global Human Albumin Industry Report 2014" report to ... Industry Report 2014 is a professional and in-depth study ... industry. The report provides a basic overview ... chain structure. The human albumin market analysis is provided ...
(Date:9/18/2014)... September 18, 2014 Leatherwood Plastics ... listed material, to stay competitive in the semiconductor, ... high-performance materials ultimately impact product quality and productivity, ... owner. , Established in 1980 in Lewisville, TX, ... many fabricators have left the business. Much of ...
(Date:9/18/2014)... SAN DIEGO , Sept. 18, 2014  MEI Pharma, ... on the clinical development of novel therapies for cancer, announced ... Chief Executive Officer, will present at BioCentury,s NewsMakers in ... at 8:30 a.m. Eastern time from the Millennium Broadway Hotel ... A live webcast of the presentation can be accessed at ...
(Date:9/18/2014)... 18, 2014 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ... concurrent but separate underwritten offerings of 10,000,000 shares of ... of $2.00 per share, for expected gross proceeds of ... Convertible Preferred Stock at a price to the public ... $20 million. Each share of Series A Convertible Preferred ...
Breaking Biology Technology:Global Human Albumin Industry Report 2014 2Global Human Albumin Industry Report 2014 3Leatherwood Plastics Selects Vycom’s Flametec PVC-C Material to Stay Competitive in Semiconductor and Lab Equipment Industries 2MEI Pharma To Present At BioCentury's NewsMakers Conference 2MEI Pharma To Present At BioCentury's NewsMakers Conference 3Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 3
... in interesting times. Not so long ago, we IT practitioners may as ... on them. What we did was a mystery to the rest of ... trick gone bad, there was a huge puff of smoke on Wall ... all the world to see. , ,Somewhere in all of that, most ...
... research could be challenged by the intervention of California ... of the Bush administration, whose campaign he supports, Schwarzenegger ... support to Proposition 71 , a California initiative ... in California the sale of $3 billion in bonds, ...
... make batteries, lights and personal grooming products, including foil ... The company employs about 5,000 people. Ben Bradley recently ... Gutknecht; Brent Leland, director of business IT; and Rick ... Sarbanes-Oxley on IT processes, myths about ROI justification and ...
Cached Biology Technology:IT leadership is not just for CIOs anymore 2Stem-cell support from Schwarzenegger could shake Wisconsin leadership 2Stem-cell support from Schwarzenegger could shake Wisconsin leadership 3Stem-cell support from Schwarzenegger could shake Wisconsin leadership 4Rayovacs IT team discusses network security, Sarbanes-Oxley and ROI myths 2Rayovacs IT team discusses network security, Sarbanes-Oxley and ROI myths 3Rayovacs IT team discusses network security, Sarbanes-Oxley and ROI myths 4Rayovacs IT team discusses network security, Sarbanes-Oxley and ROI myths 5
(Date:9/18/2014)... form of camouflage: you don,t just blend in, the ... as uncommon as you might think. Kathryn Feller, from ... the larval life stages of many marine species are ... that most creatures cannot make transparent. Feller explains that ... individual eye unit with an opaque pigment to prevent ...
(Date:9/17/2014)... Institute for the Arts and Humanities has received a ... a two-year project, "The Boundaries of the Human in ... will support a wide-ranging series of events aimed at ... One involves artists and researchers who are exploring the ... idea of humanism, and the other involves the increasingly ...
(Date:9/17/2014)... environmental impact recently scored a major win. In August, ... bags, and Governor Jerry Brown is expected to sign ... without a fight, according to an article in ... the American Chemical Society. , Alexander Tullo, a senior ... its first small victory in 1990 when Nantucket became ...
Breaking Biology News(10 mins):Transparent larvae hide opaque eyes behind reflections 2Mellon Foundation awards grant for major project in the humanities and sciences 2
... , VILNIUS, Lithuania, ... of high-precision biometric identification technologies, has released two new ... 4.0 Software Development Kit (SDK) for facial recognition ... and automated fingerprint identification systems (AFIS). Expanded capabilities in ...
... eight European countries has shown that closing schools in ... a significant role in reducing illness transmission. Researchers writing ... compared opportunities for infection on school days and ... shut. Niel Hens, from Hasselt and Antwerp University, ...
... in the stomach, may be used to boost resistance to, ... Medicine researchers report in a study published in a recent ... disease is caused by a degeneration of dopamine neurons in ... which is responsible for dopamine production. Reduced production of ...
Cached Biology News:New VeriLook 4.0 for Biometric Facial Recognition and MegaMatcher 3.1 for Multi-biometric Applications Are Now Available 2New VeriLook 4.0 for Biometric Facial Recognition and MegaMatcher 3.1 for Multi-biometric Applications Are Now Available 3School closure could reduce swine flu transmission by 21 percent 2Hormone ghrelin can boost resistance to Parkinson's disease 2
Taq DNA Polymerase (T. aquaticus), 250 units. For PCR and other procedures requiring DNA polymerase activity at elevated temperatures. Category: Nucleotides & Enzymes & Biochemicals, Modifying Enzyme...
Recombinant DNA polymerase from Thermus aquaticus expressed in E. coli; 5 units/L; 1 tube of 1, 000 units enzyme/tube w/Buffer II and MgCl2...
Recombinant DNA polymerase from Thermus aquaticus expressed in E. coli; 5 units/uL; 25 tubes of 1, 000 units enzyme/tube w/ Buffer I...
A robust formulation of Taq Polymerase supplied with a 10X colored reaction buffer which allows Direct Gel-Loading...
Biology Products: